Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sunset Island Group, Inc. (SIGO)
San Clemente, CA, US
Operating through its subsidiary, VBF Brands, Sunset Island Group, Inc. focuses on the cultivation of medicinal cannabis throughout California, United States. Furthermore, the company provides advisory and support services to various enterprises active in the medical marijuana sector. Sunset Island Group, Inc. was established in 2005 and its principal office is located in San Clemente, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -98.00% | -99.89% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+98.7% ★
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-173.7% Q3'18: -5,042.9% (vs Q3'17)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+22.7% ★
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-34.7%
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q3'18: +167.1% (vs Q3'17)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+2.1% Q3'18: -89.2% (vs Q3'17)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-3.89× Q3'18: -0.45× (vs Q3'17)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Valerie Baugher | Chief Executive Officer, President, Chief Financial Officer, Principal Accounting Officer, Secretary & Director | 18.4K | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SIGO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
